Olon (P&R Group) signed the definitive agreement to acquire INFA Group.

P&R and Infa Group shareholders have reached the deal closing for the transaction of 100% Infa shares to Olon SpA. Olon is one of the largest European developers and manufacturers, supplying APIs for the pharmaceutical industry worldwide both, for Generic as well …

Infa Group agrees to transfer 100% of its shares to Olon SpA, P&R Group subsidiary

INFA Group and P&R are pleased to announce that a binding agreement has been signed to acquire 100% of the Italian pharmaceutical chemical manufacturer, INFA Group through the P&R subsidiary, Olon S.p.A. OLON S.p.A. has 5 manufacturing sites in northern Italy with …

Labochim HPAPI Kilolab Plant “Led Zeppelin” received cGMP approval

Infa Group is pleased  to announce that LABOCHIM SpA has received the cGMP Certification  for its  new “state of the art”  Multipurpose High Potent API plant “Led Zeppelin”. The AIFA approval is dated 12 October 2015. The new Kilo Laboratory operates according to …

Vildagliptin validation successfully completed

Infa Group is pleased to announce that the validation campaign of Vildagliptin has been successfully completed by Ulkar Kimya, Infa Group strategic ally. Vildagliptin was developed at Labochim and, according to the below strategy , has been optimized and validated at our …

DCAT Announces New Officer

Robbinsville, NJ, USA, October 29, 2015 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Paolo Magri, Vice President, Corporate Business Development at Infa, Inc. has been elected by the membership to serve as third vice president …

FDA successfully completed inspection of Derivados Quimicos sau

Infa Group is pleased to announce that the US Food and Drug Administration (FDA) has successfully completed the inspection of the Spanish active pharmaceutical ingredient (API) and intermediates manufacturing facility Derivados Quimicos. The FDA inspected Derivados Quimicos  from October 19 to 22, …

New R&D Center

INFA GROUP, Italian API manufacturer since 1953, opened a new state of the art R&D Center in one of its two Italian manufacturing units SIFAVITOR. The structure hosts a highly skilled and qualified team of scientists dedicated to the Generic Pipeline of …

AIFA successfully completed inspection of Labochim

Infa Group is very pleased to announce that the Italian Health Authorities (AIFA) inspection of Labochim, has been successfully completed. AIFA inspected Labochim, one of Infa Group’s active pharmaceutical ingredient (API) manufacturing facilities, from May 25 to 29, 2015 and found the …

FDA successfully completed inspections of Sifavitor and Labochim

Infa Group is pleased to announce that the US Food and Drug Administration (FDA) successfully completed the inspections of both Italian active pharmaceutical ingredient (API) manufacturing facilities Sifavitor and Labochim. Both facilities and the quality systems used for the manufacture and release …

Certificate of Suitability for the production of Nortriptyline Hydrochloride

INFA Group is pleased to announce that effective 16 April 2015, Sifavitor one of its Italian manufacturing sites, has been granted the Certificate of Suitability for the production of Nortriptyline Hydrochloride by EDQM (European Directorate for the Quality of Medicines & Health). …

CMO Leadership Awards 2015

This year INFA Group took part for the first time to the CMO Leadership Awards, officially held on March 18th at the W Hotel in New York and annually organized by Life Science Leader magazine. In this first experience INFA Group is …